medigraphic.com
ISSN 2007-6053 (Print)
Órgano oficial de difusión de los Hospitales Regionales de Alta Especialidad (HRAE)

2011, Number 2

<< Back Next >>

Evid Med Invest Salud 2011; 4 (2)

Neurological diseases in the Oaxacan Regional Specialist Hospital, México

Monroy-Guerrero J, Velásquez-Paz A, Cervantes-González J, García-Ramos P

Language: Spanish
References: 20
Page: 48-53
PDF size: 165.21 Kb.


ABSTRACT

Introduction: Neurological diseases are a major cause of death and disability in the general population, besides causing significant socioeconomic impact in the world. The study aimed to describe the main neurological diseases treated at the Oaxacan Regional Specialist Hospital, as well as their distribution and behavior between 2006 and 2010.
Material and methods: Retrospective and descriptive study. We reviewed the reasons for consulting the neurology department recorded during February 2006 and December 2010. They use the International Classification of Diseases, Tenth Revision (ICD-10). The variables analyzed were age, gender and neurological disease.
Results: We examinated a total of 1,676 consultations in the neurology service. Just five diseases accounted for 63.7% (1,068) of all consultations; the first complaint of migraine was 20.9%, followed by 19.7% epilepsy, cerebral vascular disease 14.1%, disorders of the cranial nerves with 4.3%, Parkinson disease with 2.6% and Alzheimer's disease with 2.2%.
Discussion: Neurological diseases are an important cause of medical care at any age group in any gender in our institution. Most of these are chronic diseases that cause a drain on healthcare resources.


REFERENCES

  1. Levi-Montaicini R. Prologue. Neurological Disorders: Public health challenges. World Health Organization, 2007 (Internet). Disponible en http://www. who.int/mental_health/ neurology/neurodiso/en/index.html [12.02.2011].

  2. Pradilla AG , Vesga BE, León-Sarmi ento FE, Grupo GENECO . Estudio neuroepi demi ológico nacional (EPINEURO ) colombiano. Rev Panam Salud Publica 2003; 14 (2): 104-111.

  3. Corona-Vásquez T. Las enfermedades neurológicas. Su dimensión y repercusión social. Gac Méd Méx 2002; 138 (6): 533-546.

  4. Organización Mundial de la Salud. Los trastornos neurológicos afectan a mi - llones de personas en todo el mundo: informe de la OMS. 2007 (Internet). Disponible en http://www .who.int/mediacentre/ news/releases/2007/pr04/ es/index.html [12.02.2011].

  5. Tarun D, Marco-Garrido C, Colin M, Shekhar S. Carga global de los trastornos neurológicos: estim aciones y proyecciones. En Neurological Disorders: Public health challenges. World Health Organization, 2007. p. 29-43. (Internet). Disponible en http://www. who.int/mental_health/ neurology/neurodiso/en/index.html [12.02.2011].

  6. Jiménez Marcial ME, Velásquez Pérez L. Morbilidad en el Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez" 1995-2001. Gac Méd Méx 2004; 140 (2): 155-162.

  7. Rubio-Ronnadieu F. Epi lepsia. Programa Prioritario de Epilepsia. 2007: 26-30

  8. Rasmussen BK. Epi demi ology of mi graine. Biomed Pharmacother 1995; 49 (10): 452-455.

  9. Avila-Funes JA, Gutierrez_robledo LM, Ponce De Leon RS. Validity of height and wei ght self-report in Mexican adults: results from the national health and aging study. J Nutr Health Aging 2004; 8 (5): 355-361.

  10. Téllez-Zenteno JF, García-Ramos G, Zermeño-Pöhls, Velázquez A, GGSM. Demographi c, clinical and comorbidity data in a large simple of 1147 patients with migraine in Mexico City. J Headache Pain 2005; 6: 128-134.

  11. Tepper SJ, Meddis D. Reducing the cost of imp ai rment of Normal Activities due to Migraine: a Stratified-Care App roach. Headache 2000; 40: 434-435.

  12. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes and consequences. New York: demos; 1990:1-51.

  13. So EL. Classiffications and epidemiologic considerations of epileptic seizures and epilepsy. Neuroimaging Clin N Am 1995; 5: 513-526.

  14. Serrano-Martín J. Aspectos epidemiológicos de la epilepsia en un Hospital General de Segundo Nivel. Plast & Rest Neurol 2004; 34 (1 y 2): 39-43.

  15. Barinagarrementeria AF, Araúz- Góngora A, Cantú-Brito C. Consenso Mexicano de Prevención y Tratamiento de la Enfermedad Vascular Cerebral. Rev Invest Clin 2002; 54 (3): 245- 246.

  16. Enfermedad Vascular Cerebral. Primera causa de discapacidad. Comunicado de prensa Núm. 346, 10/Agosto/2010. Subsecretaría de Prevención y Promoción de la Salud. (Internet). Disponible en http://www .spp s.gob.mx/ noticias/81-enfermedad-vascular-cerebral- prim era-causa-de-discapacidad-. html [12.02.2011].

  17. Jacson CG , von Doersten PG. The Facial Nerve, Current trends in diagnosis, treatment, and rehabilitation. Med Clin North Am 1999; 83: 179-95.

  18. López-Carbajal, MJ. Identificación de factores de riesgo en el desarrollo de parálisis facial idiopática en población derechohabiente del Instituto Mexicano del Seguro Social (tesis). México, IMSS.

  19. Parkinson´s Disease. National clinical guideline for diagnosis and management in primary and secondary care. Royal College of Physicians, 2006.

  20. Informe Mundial sobre el Alzheim er 2010. Alzheim er's Disease International. (Internet). Disponible en http:// www .alz.co.uk [20.02.2011].




2020     |     www.medigraphic.com